Molecular approaches to discover marine natural product anticancer leads - An update from a Drug Discovery Group Collaboration

Pharmaceutical Biology

Volumn 41, Issue SUPPL., 2003, Pages 39-52

  Crews, Phillip ^a   Gerwick, William H ^b   Schmitz, Francis J ^c   France, Dennis ^d   Bair, Kenneth W ^d   Wright, Amy E ^e   Hallock, Yali ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c UNIVERSITY OF OKLAHOMA   (United States)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 5 METHOXYAMPHIMEDINE; ALKALOID; ALPKINIDINE; ANTINEOPLASTIC AGENT; APLYRONINE A; BRYOSTATIN 1; CURACIN A; DISCODERMOLIDE; DOLASTATIN 10; ELEUTHEROBIN; ES 285; FASCAPLYSIN; HALICHONDRIN B; HEMIASTERLIN A; HEMIASTERLIN B; ISOGRANULATAMIDE; ISOHOMOHALICHONDRIN B; KAHALALIDE F; LAF 389; LAULIMALIDE; NATURAL PRODUCT; POLYPEPTIDE; SALINOSPORAMIDE; SQUALAMINE; STEROID; THIOCORALINE; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACTINOMYCES; ANTINEOPLASTIC ACTIVITY; BRYOZOA; CANCER; CANCER RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; COOPERATION; DRUG INDUSTRY; DRUG ISOLATION; DRUG RESEARCH; DRUG SCREENING; HUMAN; MARINE ENVIRONMENT; MOLLUSC; NONHUMAN; SHARK; SPONGE (PORIFERA);

ACTINOMYCES; BRYOZOA; CHONDRICHTHYES; MOLLUSCA; PORIFERA;

EID: 9444229925     PISSN: 13880209     EISSN: None     Source Type: Journal    
DOI: 10.1080/1388020039051743     Document Type: Conference Paper

References (51)

1. Abad MJ, Bermejo P (2001): Bioactive natural products from marine sources. In: Atta-ur-Rahman, ed., Studies in Natural Products Chemistry. Elsevier, Amsterdam, pp. 683-756.
2. Abel U, Koch C, Speitling M, Hansske FG (2002): Modern methods to produce natural-product libraries. Curr Opin Chem Biol 6: 453-458.
3. Arabshahi L, Schmilz FJ (1987): Brominated tyrosine metabolites from an unidentified sponge. J Org Chem 52: 3584-3586.
4. Broggini M, Marchini SV, Galliera E, Borsotti P, Taraboletti G, Erba E, Sironi M, Jimeno J, Faircloth GT, Giavazzi R, D'Incalci M (2003): Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia 17: 52-59.
5. Capon RJ (2001); Marine bioprospecting - Trawling for treasure and pleasure. Eur J Org Chem 633-645.
6. Cimino G, De Rosa S, De Stefano S (1984): Experientia 40: 339-340.
7. Crews P, Slate DL, Gerwick WH, Schmilz FJ, Schatzman R, Strulovici B, Cannon P, Hunter LM (1991): In: Valeriote FA, Corbett TH, Baker LH, eds., Anticancer Drug Discovery and Development: Natural Products and New Molecular Models. Kluwer Academic Publishers, Boston, pp. 365-399.
8. Evans JS, Musser EA, Mengel GD, Forsblad KR, Hunter JH (1961): Antitumor activity of 1-beta-D-arainofuranosylcytosine hydrochloride. Proc Soc Exp Biol Med 106: 350-353.
9. Faulkner DJ (2000): Marine pharmacology. Anton Leeuw Int J G 77: 135-145.
10. Fournel M, Sapieha P, Beaulieu N, Besterman J, MacLeod A (1999): Down-regulation of human DNA-(cytosine-5) methyltransferase induces cell cycle regulators p16(ink4A) and p21(WAF/Cip1) by distinct mechanisms. J Biol Chem 274: 24250-24256.
11. Freudenthal HD (ed.), Proceedings of the conference U. Rhode Island, sponsored by Marine Technology Society, 1967.
12. Fusetani N (2000): Introduction. In; Fusetani N, ed., Drugs from the Sea. Karger, Basel, pp. 1-5.
13. Grant S, Roberts J, Poplin E, Tombes MB, Kyle B, Welch D, Carr M, Bear HD (1998): Phase Ib trial of bryostatin 1 in patients with refractory malignancies. Clin Cancer Res 4: 611-618.
14. Gunawardana GP, Koehn FE, Lee AY, Clardy J, He HY, Faulkner DJ (1992); Pyridoacridine alkaloids from deep-water marine sponges of the family Pachastrellidae: Structure revision of dercitin and related compounds and correlation with the kuanoniamines. J Org Chem 57: 1523-1526.
15. Hamann MT, Scheuer PJ (1993): Kahalalide F: a bioactive depsipeptide from the sacoglasson mollusk Elysia rufescens and the green alga Bryopsis sp. J Am Chem Soc 115: 5825-5826.
16. Hendrich B, Bird A (1998): Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol 18: 6538-6547.
17. Henkle T, Brunne RM, Müller H, Reichel F (1999): Statistical investigation into the structural complementarity of natural products and synthetic compounds. Angew Chem Int Ed 38: 643-647.
18. Höller U, Wright AD, Matthée GF, König GM, Draeger S, Aust H-J, Schulz B (2000): Fungi from marine sponges: Diversity, biological activity and secondary metabolites. Mycol Res 104: 1354-1365.
19. Huang Y, Tan M, Gosink M, Wang K, Sun Y (2002): Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis. Cancer Res 62: 2913-2922.
20. Jiménez C, Crews P (1991): Novel marine sponge derived amino acids 13. Additional psammaplin derivatives from Psammaplysilla purpurea. Tetrahedron 47: 2097-2102.
21. Jung M, Hoffmann K, Brosch G, Loidl P (1997): Analogues of trichosatin A and trapoxin B as histone deacetylase inhibitors. Bioorg Med Chem Lett 7: 1655-1658
22. Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T (1993): Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem 268: 22429-22435.
23. Kinder FR Jr (2002): Synthetic approaches toward the bengamide family of antitumor marine natural products. A review. Org Prep Proced Int 66: 559-583.
24. Lee WW, Benitoez A, Goodman L, Baker BR (1960): Potential anticancer agents. XL. Synthesis of the β-anomer of 9-(D-arabinofuranosyl)-adenine. J Am Chem Soc 82: 2648-2649.
25. Medina V, Edmonds B, Young G, James R, Appleton S, Zalewski P (1997): Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): Dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res 57: 3697-3707.
26. Milutinovic S, Knox J, Szyf M (2000): DNA methyltransferase inhibition induces the transcription of the tumor suppressor p21(WAF1/CIP1/sdi1). J Biol Chem 275: 6353-6359.
27. Moore KS, Wehrli S, Roder H, Rogers M, Forrest JN, McCrimmon D, Zasloff M (1993): Squalamine: An aminosterol antibiotic from the shark. Proc Natl Acad Sci USA 90: 1354-1358.
28. Munro HG, Blunt JW, Dumdei EJ, Hickford SJH, Lill RE, Li S, Battershill CN, Duckworth AR (1999): The Discovery and development of marine compounds with pharmacetuical potential. J Biotechnol 70: 15-25.
29. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S (1998): FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exptl Cell Res 241: 126-133.
30. Newman DJ, Cragg GM, Snader KM (2003): Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 66: 102-1037.
31. North TW, Cohen SS (1979); Aranucleosides and aranucleotides in viral chemotherapy. Pharmacol Ther 4: 81-108.
32. Pettit GR (1987): The Bryostatins. In: Herz W, Grisebach H, Kirby GW, Tamm C, eds., Progress in the Chemistry of Organic Natural Products. Springer-Verlag, New York, pp. 153-195.
33. Piña IC, Gautschi JT, Wang G-Y-S, Sanders ML, Schmilz FJ, France D, Cornell-Kennon S, Sambucetti LC, Remiszewski SW, Perez LB, Bair KW, Crews P (2003): Psammaplins from the sponge Pseudoceratina purpurea: Inhibition of both histone deacetylase and DNA methyltransferase. J Org Chem 68: 3866-3877.
34. Proksch P, Edrada RA, Ebel R (2002): Drugs from the seas - Current status and microbiological implications. Appl Microbiol Biotechnol 59: 125-134.
35. Quiñoá E, Crews P (1987): Phenolic constituents of Psammaplysilla. Tetrahedron Lett 28: 3229-3232.
36. Ramchandani S, MacLeod A, Pinard M, von Hofe E, Szyf M (1997): Inhibition of tumorigenesis by a cytosine-DNA, methyltransferase, antisense oligodeoxynucleotide. Proc Natl Acad Sci USA 94: 684-692.
37. Remiszewski SW, Sambucetti LC, Atadja P, Bair KW, Bontempo J, Cesarz D, Chandramouli N, Chen R, Dean K, Diamantidis G, Green MA, Howell KL, Kashi R, Kwon P, Lassota P, Mou Y, Nemzek R, Perez LB, Sorensen E, Taplin F, Trogani N, Versace R, Walker H, Weltchek-Engler S, Wood AW, Wu A (2002): Discovery of NVP-LAQ284, a novel histone deacetylase inhibitor with in vitro and in vivo antitumor activity. Abs 224th Natl ACS MEDI-Part 2: 227
38. Remiszewski SW, Sambucetti LC, Atadja P, Bair KW, Cornell WD, Green MA, Howell KL, Jung M, Kwon P, Trogani N, Walker H (2002): Inhibitors of human histone deacetylase: Synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem 45: 753-757.
39. Rodriguez AD, Akee RK, Scheuer PJ (1987): Two bromotyrosine-cysteine derived metabolites from a sponge. Tetrahedron Lett 28: 4989-4992.
40. Rinehart KL, Holt TG, Fregeau NL, Stroh JG, Keifer PA, Sun F, Li LH, Martin DG (1990): Ecteinascidins 729, 743, 745, 759A, 759B, and 770: Potent antitumor agents from the Caribbean tunicate Ecteinasddia turbinate. J Org Chem 55: 4512-4515.
41. Rountree MR, Bachman KE, Herman JG, Baylin SB (2001): DNA methylation, chromatin inheritance, and cancer. Oncogene 20: 3156-3165.
42. Sakai R, Rinehart KL, Kishore V, Kundu B, Faircloth G, Gloer JB, Carney JR, Namikoshi M, Sun F, Hughes RG Jr, Grávalos DG, de Quesada TG, Wilson GR, Heid RM (1996): Structure-activity relationships of the didemnins. J Med Chem 39: 2819-2834.
43. Sambucetti L, Fischer D, Zabludoff S, Kwon P, Chamberlin H, Trogani N, Xu H, Cohen D (1999): Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 274: 34940-34947.
44. Shu Y-Z (1998): Recent natural products based drug development: A pharmaceutical industry perspective. J Nat Prod 61: 1053-1071.
45. For a review of these projects see: Suffness M, Cragg GM, Grever MR, Grifo FJ, Johnson G, Mead JAR, Schepartz SA, Venditti JM, Wolpert M (1995): The nationa-cooperative-natural-products-drug-discovery-group (NCDDG) and international-cooperative-biodiversity-group (ICBG) programs. Int J Pharmacogn 33(Suppl S): 5-16.
46. Taunton J, Collins JL, Schreiber SL (1996): Synthesis of natural and modified trapoxins, useful reagents for exploring histone deacetylase function. J Am Chem Soc 118: 10412-10422.
47. Wright AE (1998): In: Natural products isolation methods in biotechnology, Vol 4. (R.J.P. Cannell, ed.), Humana Press Inc. (Totowa, NJ), pp. 365-408.
48. Yamada K, Higuchi R (2001): Bioactive diterpenoids from Japanese soft corals. In: Bioactive Compounds from Natural Sources Taylor & Francis: London, 2001, pp. 639-674.
49. Yoshida M, Kijima M, Akita M, Beppu T (1990): Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265: 17174-17179.
50. Yoshida M, Horinouchi S, Beppu T (1995): Trichostatin A and trapoxin: Novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays 77:423-430.
51. Zhu W, Lakshmanan R, Beal M, Otterson G (2001): DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 61: 1327-1333.